Aristides Capital LLC Phathom Pharmaceuticals, Inc. Transaction History
Aristides Capital LLC
- $260 Million
- Q4 2024
A detailed history of Aristides Capital LLC transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Aristides Capital LLC holds 25,200 shares of PHAT stock, worth $65,016. This represents 0.08% of its overall portfolio holdings.
Number of Shares
25,200Holding current value
$65,016% of portfolio
0.08%Shares
1 transactions
Others Institutions Holding PHAT
# of Institutions
157Shares Held
67.6MCall Options Held
52.3KPut Options Held
635K-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.1MShares$26.1 Million4.92% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$19.3 Million12.73% of portfolio
-
Jennison Associates LLC7.04MShares$18.2 Million0.03% of portfolio
-
Invesco Ltd. Atlanta, GA3.67MShares$9.47 Million0.01% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$9.02 Million27.15% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $101M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...